Octreotide Therapy for Chylous Ascites

Mechanism of Action and Efficacy

Octreotide, a somatostatin analog, decreases gastric, biliary, and pancreatic secretions, reducing splanchnic blood flow and portal pressure, and inhibiting the release of various hormones that may contribute to fluid accumulation, thereby decreasing intestinal motility and improving intestinal absorption in patients with chylous ascites 1
Octreotide reduces splanchnic blood flow and portal pressure, which can help alleviate symptoms of chylous ascites 2

The American Gastroenterological Association recommends considering octreotide therapy when initial conservative measures fail to resolve chylous ascites, with a recommended dosing of subcutaneous octreotide 100 μg three times daily 3
Monitoring for potential side effects including nausea, hyperglycemia, and abdominal pain is necessary when initiating octreotide therapy 4

In patients with hepatorenal syndrome, octreotide may be combined with midodrine and albumin for additional benefit, as recommended by the European Association for the Study of the Liver 2, 3
For long-term management, octreotide LAR (long-acting release) formulation may be considered after establishing optimal dosing with the short-acting form, according to the American College of Gastroenterology 4